Institution
Université Paris-Saclay
Education•Gif-sur-Yvette, France•
About: Université Paris-Saclay is a education organization based out in Gif-sur-Yvette, France. It is known for research contribution in the topics: Population & Context (language use). The organization has 29307 authors who have published 43183 publications receiving 867404 citations.
Topics: Population, Context (language use), Computer science, Medicine, Laser
Papers published on a yearly basis
Papers
More filters
••
Icahn School of Medicine at Mount Sinai1, Radboud University Nijmegen2, Technische Universität München3, Niigata University4, National and Kapodistrian University of Athens5, Université Paris-Saclay6, Medical University of Vienna7, University of Texas Southwestern Medical Center8, Charles University in Prague9, I.M. Sechenov First Moscow State Medical University10, Samsung Medical Center11, Fudan University12, Aarhus University Hospital13, Guy's and St Thomas' NHS Foundation Trust14, Rambam Health Care Campus15, University of North Carolina at Chapel Hill16, Bristol-Myers Squibb17
TL;DR: In this article, the role of adjuvant treatment in high-risk muscle-invasive urothelial carcinoma after radical surgery was not clear, and a phase 3, multicenter, double-blind, randomized, controlled trial was conducted.
Abstract: Background The role of adjuvant treatment in high-risk muscle-invasive urothelial carcinoma after radical surgery is not clear. Methods In a phase 3, multicenter, double-blind, randomized, controlled trial, we assigned patients with muscle-invasive urothelial carcinoma who had undergone radical surgery to receive, in a 1:1 ratio, either nivolumab (240 mg intravenously) or placebo every 2 weeks for up to 1 year. Neoadjuvant cisplatin-based chemotherapy before trial entry was allowed. The primary end points were disease-free survival among all the patients (intention-to-treat population) and among patients with a tumor programmed death ligand 1 (PD-L1) expression level of 1% or more. Survival free from recurrence outside the urothelial tract was a secondary end point. Results A total of 353 patients were assigned to receive nivolumab and 356 to receive placebo. The median disease-free survival in the intention-to-treat population was 20.8 months (95% confidence interval [CI], 16.5 to 27.6) with nivolumab and 10.8 months (95% CI, 8.3 to 13.9) with placebo. The percentage of patients who were alive and disease-free at 6 months was 74.9% with nivolumab and 60.3% with placebo (hazard ratio for disease recurrence or death, 0.70; 98.22% CI, 0.55 to 0.90; P Conclusions In this trial involving patients with high-risk muscle-invasive urothelial carcinoma who had undergone radical surgery, disease-free survival was longer with adjuvant nivolumab than with placebo in the intention-to-treat population and among patients with a PD-L1 expression level of 1% or more. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 274 ClinicalTrials.gov number, NCT02632409.).
289 citations
••
University of Liège1, French Institute of Health and Medical Research2, University of Buenos Aires3, Collège de France4, Université Paris-Saclay5, Pompeu Fabra University6, National Scientific and Technical Research Council7, University of Birmingham8, University of Western Ontario9, Columbia University10, Cornell University11
TL;DR: The results establish that consciousness rests on the brain’s ability to sustain rich brain dynamics and pave the way for determining specific and generalizable fingerprints of conscious and unconscious states.
Abstract: Adopting the framework of brain dynamics as a cornerstone of human consciousness, we determined whether dynamic signal coordination provides specific and generalizable patterns pertaining to conscious and unconscious states after brain damage. A dynamic pattern of coordinated and anticoordinated functional magnetic resonance imaging signals characterized healthy individuals and minimally conscious patients. The brains of unresponsive patients showed primarily a pattern of low interareal phase coherence mainly mediated by structural connectivity, and had smaller chances to transition between patterns. The complex pattern was further corroborated in patients with covert cognition, who could perform neuroimaging mental imagery tasks, validating this pattern’s implication in consciousness. Anesthesia increased the probability of the less complex pattern to equal levels, validating its implication in unconsciousness. Our results establish that consciousness rests on the brain’s ability to sustain rich brain dynamics and pave the way for determining specific and generalizable fingerprints of conscious and unconscious states.
288 citations
•
31 Jul 2014
288 citations
••
TL;DR: In this article, the sky localization of the first observed compact binary merger is presented, where the authors describe the low-latency analysis of the LIGO data and present a sky localization map.
Abstract: A gravitational-wave (GW) transient was identified in data recorded by the Advanced Laser Interferometer Gravitational-wave Observatory (LIGO) detectors on 2015 September 14. The event, initially designated G184098 and later given the name GW150914, is described in detail elsewhere. By prior arrangement, preliminary estimates of the time, significance, and sky location of the event were shared with 63 teams of observers covering radio, optical, near-infrared, X-ray, and gamma-ray wavelengths with ground- and space-based facilities. In this Letter we describe the low-latency analysis of the GW data and present the sky localization of the first observed compact binary merger. We summarize the follow-up observations reported by 25 teams via private Gamma-ray Coordinates Network circulars, giving an overview of the participating facilities, the GW sky localization coverage, the timeline, and depth of the observations. As this event turned out to be a binary black hole merger, there is little expectation of a detectable electromagnetic (EM) signature. Nevertheless, this first broadband campaign to search for a counterpart of an Advanced LIGO source represents a milestone and highlights the broad capabilities of the transient astronomy community and the observing strategies that have been developed to pursue neutron star binary merger events. Detailed investigations of the EM data and results of the EM follow-up campaign are being disseminated in papers by the individual teams.
288 citations
••
TL;DR: It is demonstrated that oxaliplatin-induced DNA lesions, including ISC and DPC, are likely to contribute to the drug's biological properties and requires fewer DNA lesions than does cisplatin to achieve cell growth inhibition.
Abstract: Damage to cellular DNA is believed to determine the antiproliferative properties of platinum (Pt) drugs. This study characterized DNA damage by oxaliplatin, a diaminocyclohexane Pt drug with clinical antitumor activity. Compared with cisplatin, oxaliplatin formed significantly fewer Pt-DNA adducts (e.g., 0.86+/-0.04 versus 1.36+/- 0.01 adducts/10(6) base pairs/10 microM drug/1 h, respectively, in CEM cells, P<.01). Oxaliplatin was found to induce potentially lethal bifunctional lesions, such as interstrand DNA cross-links (ISC) and DNA-protein cross-links (DPC) in CEM cells. As with total adducts, however, oxaliplatin produced fewer (P<.05) bifunctional lesions than did cisplatin: 0.7+/-0.2 and 1.8+/-0.3 ISC and 0.8+/-0.1 and 1.5+/-0.3 DPC/10(6) base pairs/10 microM drug, respectively, after a 4-h treatment. Extended postincubation (up to 12 h) did not compensate the lower DPC and ISC levels by oxaliplatin. ISC and DPC determinations in isolated CEM nuclei unequivocally verified that oxaliplatin is inherently less able than cisplatin to form these lesions. Reactivation of drug-treated plasmids, observed in four cell lines, suggests that oxaliplatin adducts are repaired with similar kinetics as cisplatin adducts. Oxaliplatin, however, was more efficient than cisplatin per equal number of DNA adducts in inhibiting DNA chain elongation ( approximately 7-fold in CEM cells). Despite lower DNA reactivity, oxaliplatin exhibited similar or greater cytotoxicity in several other human tumor cell lines (50% growth inhibition in CEM cells at 1.1/1.2 microM, respectively). The results demonstrate that oxaliplatin-induced DNA lesions, including ISC and DPC, are likely to contribute to the drug's biological properties. However, oxaliplatin requires fewer DNA lesions than does cisplatin to achieve cell growth inhibition.
288 citations
Authors
Showing all 29679 results
Name | H-index | Papers | Citations |
---|---|---|---|
Guido Kroemer | 236 | 1404 | 246571 |
Patrick O. Brown | 183 | 755 | 200985 |
Didier Raoult | 173 | 3267 | 153016 |
Sophie Henrot-Versille | 171 | 957 | 157040 |
Philippe Ciais | 149 | 965 | 114503 |
Stanislas Dehaene | 149 | 456 | 86539 |
Marc Humbert | 149 | 1184 | 100577 |
Jean Bousquet | 145 | 1288 | 96769 |
Jean-François Cardoso | 145 | 373 | 115144 |
Marc Besancon | 143 | 1799 | 106869 |
Maksym Titov | 139 | 1573 | 128335 |
W. Kozanecki | 138 | 1498 | 99758 |
Nabila Aghanim | 137 | 416 | 100914 |
Yves Sirois | 137 | 1334 | 95714 |
Patrick Janot | 136 | 1485 | 93626 |